Ginkgo Bioworks HoldingsDNABW -18.18%63 Gross Margin % is 84.09% as of Mar. 2026, which is 11% above its 10-year median of 75.46. GuruFocus rates DNABW with a GF Score™ of 63/100. The stock has 5 warning signs investors should review. Among 737 Biotechnology companies, Ginkgo Bioworks Holdings ranks better than 62.96% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ginkgo Bioworks Holdings had a gross margin of 84.09% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ginkgo Bioworks Holdings Gross Margin % Related Terms
Ginkgo Bioworks Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNABW vs CADL, CABA, CLYM: Gross Margin % Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ginkgo Bioworks Holdings (DNABW) has a Gross Margin % of 84.09% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ginkgo Bioworks Holdings and its competitors. This is 11% above median its historical median of 75.46. Over the past decade, Ginkgo Bioworks Holdings' Gross Margin % has ranged from 57.25 to 80.38. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #273 out of 737 companies in the Biotechnology industry, placing it in the top 37%.
Is Ginkgo Bioworks Holdings' Gross Margin % too high?
Ginkgo Bioworks Holdings' current Gross Margin % of 84.09% is 11% above median its 10-year median of 75.46. Over the past 10 years, this metric has ranged from a low of 57.25 to a high of 80.38. The Biotechnology industry median Gross Margin % is 60.92. Ginkgo Bioworks Holdings' value of 84.09% is 38% above this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #273 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Gross Margin % compare to CADL and CABA?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #273 out of 737 companies for Gross Margin %. This puts Ginkgo Bioworks Holdings in the upper half of its industry. The industry median Gross Margin % is 60.92. Ginkgo Bioworks Holdings' value of 84.09% is 38% above this benchmark. Historically, Ginkgo Bioworks Holdings' own Gross Margin % has ranged from 57.25 to 80.38 over the past decade. While the company's 10-year median is 75.46 vs. the industry median of 60.92, Ginkgo Bioworks Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current Gross Margin % of 84.09% is 38% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Gross Margin % is 84.09%, which is 11% above median its own 10-year median of 75.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Ginkgo Bioworks Holdings (DNABW) has a current Gross Margin % of 84.09%. The current Gross Margin % is 84.09%, which is 11% above median its 10-year median of 75.46 and 38% above the Biotechnology industry median of 60.92. Ginkgo Bioworks Holdings' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNABW), the current Gross Margin % is 84.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
63GF Score
Get the complete analysis for DNABW
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNABW has been successfully added to your 
